ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe
July 27 2018 - 6:00AM
Business Wire
ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today confirmed, that
Dr. Ronan Lambe retired as a non-executive director at the Annual
General Meeting (AGM) of the Company on the 24th July 2018. This
follows the announcement in the 2018 AGM Notice, dated 12th June
2018, that Dr. Lambe had decided to retire and not seek re-election
at the AGM.
CEO Dr. Steve Cutler commented, “I would like to recognize the
immense contribution of Dr. Ronan Lambe, ICON’s co-founder with Dr.
John Climax, who after 28 years of service, has retired from our
Board. We thank Ronan for the hugely positive influence he has had
on shaping ICON into the industry leader it is today, and we wish
him well in his retirement.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 93 locations in 37 countries and has approximately
13,650 employees. Further information is available at
www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180727005016/en/
ICON plcInvestor Relations+1 888 381 7923orBrendan
BrennanChief Financial Officer+353 1 291 2000orJonathan CurtainVice
President Corporate Finance and Investor Relations+1 215 616
3000
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024